**3. Evolving modes and mechanisms of ACT**

ACT developed in different ways has different mechanisms to target cancer cells. These are the foremost cellular technology adopted for cancer treatment after their validations and regulations through various clinical trials.

**123**

**Figure 3.**

*steps of these therapies discussed in the boxes.*

*Advances in Adoptive Cellular Therapy (ACT) DOI: http://dx.doi.org/10.5772/intechopen.95854*

as these are derived from the tumor site.

function of the infused TILs [37].

**3.2 Genetic manipulations of T cells**

**3.1 Tumor infiltrating lymphocytes (TILs)**

Under the immune surveillance, lymphocytes differentiate between self and non-self-cells and antigens. Any self-cell when gets transformed and starts proliferating as cancer, lymphocytes infiltrate into that site, recognize abnormally growing cells and activate themselves to remove these *not so self*, cancerous cells. These lymphocytes are named as Tumor Infiltrating Lymphocytes (TILs). It so happens sometimes that these TILs fail to perform their function efficiently which may lead to cancer progression. In such cases, it was found that the TILs are not enough in number to show effective cytotoxicity, though have ability to specifically recognize tumor cells, stop their growth and eventually kill them. Thus, to develop any cellular therapy, the first and the foremost approach was to expand TILs, which have infiltrated into the tumor site with anti-tumor potential. These cells can be isolated from cancer origin tissue by resection and expanded *ex-vivo* to a sufficient number to improve their anti-tumor activity. These are then infused back into the patient as ACT therapy (**Figure 3a**). The TILs used in the therapy are autologous lymphocytes

Hence, for the development of ACT, antitumor lymphocytes are grown *in-vitro* up to a number of 1011–1012, followed by a process of selection of specific tumor recognizing cells with effector functions. These cells when infused in the patient, behave like live drug, which proliferate when encounter tumor antigen in the host and help in tumor regression. Though the process of cellular expansion *in-vitro* does not absolutely match with *in-vivo* environment around the tumor, which has certain immune inhibitory responses. Thus, in ACT, a favorable tumor microenvironment is necessary prior to the therapy which should support the anti-tumor immune

Sometimes in certain cases, tumor infiltrated T cells do not recognize tumor cells and hence they neither get activated nor proliferated *in-vivo*. In such cases, T cells' usefulness becomes redundant. To improve the functional properties of these cells including recognition of antigen on cancer cells, an alternative approach is adopted

*Leading adoptive cellular therapy. Patients' T cells utilized in TILs, TCR T cells and CAR T cell therapy. Major* 

*Advances in Precision Medicine Oncology*

The concept of ACT was first developed more than fifty-five years back when immune lymphocytes were successfully used to inhibit growth of sarcoma in an

Further, efforts were made to augment the potential of ACT by inducing activation and proliferation of immune cells in use, which was achieved by the use of recombinant IL2. The IL-2 has been known to potentiate immunological functions

In cell based or cellular therapy, autologous or allogenic stem cells, progenitor or primary cells were the choice of possible cell types, which were modified *ex-vivo* and transfused into the patient for disease regression [2, 18, 19]. Cellular therapy's outcomes were better studied in the case of cancer as it was easy to readout its regression and thus, cancer was chosen first for treatment by cellular therapy. However, lately, this strategy has also been tested for treating cardiovascular, neurological and bone diseases [23]. The choice of cells to develop immunotherapy was from innate and adaptive immune systems as these cells play a key role in control-

Further, initial failures of cell- based therapy were reported due to the role of T cells as the mediators of allograft rejection and also due to the host immune inhibitory factors [2, 25]. Therefore, measures were taken prior to ACT such as use of syngeneic lymphocytes for transfer to minimize the failures of the same [25]. Thus, ACT was developed as a biomedical procedure where the immune cells of the cancer patient, which have high anticancer activity, are expanded, modified and returned

During eighties, the antitumor activities were reported in cells like natural killer (NK) and lymphokine-activated killer cells [26–30]. These cells directly recognize antigens present on tumor cells and kill them, whereas T cells recognize tumor antigens when presented with major histocompatibility complex (MHC) [31]. However, each cell has different anti-tumor potential. With advancements in immuno-technologies, such as fluorescence activated cell sorter, molecular markers were assigned on various immune cells to define them properly [32, 33]. This led to the classification of lineages and subtypes of immune cells. Thus, selection of cells

So far various cell types such as stem cells, T cells, dendritic cells and NK cells from patients are successfully used and have shown promising results in cancer regression (**Figure 1**). Dendritic cells (DCs) regulate innate immune response and due to its nature of antigen presentation, it may induce adaptive response. Tumor antigen exposed DCs may play a critical role in enhancing cytotoxic activities of immune cells. Therefore, DCs are used as an anti-tumor therapeutic vaccines or to enhance the stimulation of cytotoxic T cells by appropriate antigen

Different subset of T cells (gamma/delta T cells, regulatory T cells, helper and cytotoxic T lymphocytes) respond differently for various tumor subtypes [35]. Interestingly, some T cell subtypes confer advantage over other in reducing tumor

ACT developed in different ways has different mechanisms to target cancer cells. These are the foremost cellular technology adopted for cancer treatment after their

was made and this followed their manipulation *ex-vivo* for ACT.

**3. Evolving modes and mechanisms of ACT**

validations and regulations through various clinical trials.

and later, its use as T cell growth factor were also recommended [22].

**2. Emergence of ACT**

ling cancer progression [24].

to the patients [2, 18, 19].

presentation [34].

volume [36].

animal model [21].

**122**
